A novel mutation in CEBPA gene in a patient with acute myeloid leukemia

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Leukemia and Lymphoma

• Publication date

  2016-03-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2015.1065979PMID 26419342
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• MutationTaster2: mutation prediction for the deep-sequencing age

  2014cited by this paper
• Cytogenetics of Acute Leukemia

  2013cited by this paper
• University of Groningen Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia Hollink,

  2011cited by this paper
• Characterization of CEBPA mutations and promoter hypermethylation in pediatric acute myeloid leukemia

  2009cited by this paper
• Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation

  2009cited by this paper
• Complexity of CEBPA Dysregulation in Human Acute Myeloid Leukemia

  2009cited by this paper
• The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication.

  2009cited by this paper
• Intrinsic disorder prediction from the analysis of multiple protein fold recognition models

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Prediction of protein stability changes for single‐site mutations using support vector machines

  2005cited by this paper
• Characterization of CEBPA Mutations in Acute Myeloid Leukemia: Most Patients with CEBPA Mutations Have Biallelic Mutations and Show a Distinct Immunophenotype of the Leukemic Cells

  2005cited by this paper
• CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations.

  2004cited by this paper
• Mutation of CEBPA in familial acute myeloid leukemia.

  2004cited by this paper
• Cytogenetics in acute leukemia.

  2004cited by this paper
• Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML.

  2003cited by this paper
• Establishment of the acute myeloid leukemia cell line Kasumi‐6 from a patient with a dominant‐negative mutation in the DNA‐binding region of the C/EBPα gene

  2003cited by this paper
• Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias.

  2002cited by this paper
• Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein a in myelodysplastic syndromes and acute myeloid leukemias

  2002cited by this paper
• Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia.

  2001cited by this paper
• Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-α (C/EBPα), in acute myeloid leukemia

  2001cited by this paper
• Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice.

  1997cited by this paper
• Brief Report Results and Discussion

  year unknowncited by this paper
• Brief Report Results and Discussion

  year unknowncited by this paper

• In Silico Genetics Revealing Novel Mutations in CEBPA Gene Associated with Acute Myeloid Leukemia

  2019cites this paper
• In Silico Genetics Revealing 5 Mutations in CEBPA Gene Associated With Acute Myeloid Leukemia

  2019cites this paper